{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T01:44:47Z","timestamp":1773625487000,"version":"3.50.1"},"reference-count":167,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hospital Infection"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1053\/jhin.2002.1278","type":"journal-article","created":{"date-parts":[[2003,4,5]],"date-time":"2003-04-05T04:53:13Z","timestamp":1049518393000},"page":"243-258","source":"Crossref","is-referenced-by-count":75,"title":["Systemic mycoses in the immunocompromised host: an update in antifungal therapy"],"prefix":"10.1053","volume":"53","author":[{"given":"D.P.","family":"Kontoyiannis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Mantadakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Samonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/jhin.2002.1278_RF1","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1093\/clinids\/17.Supplement_2.S487","article-title":"Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management","volume":"17","author":"Vartivarian","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1034\/j.1399-3062.1999.010404.x","article-title":"Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century","volume":"1","author":"Walsh","year":"1999","journal-title":"Transpl Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/322606","article-title":"Trends in mortality due to invasive mycotic diseases in the United States, 1980\u20131997","volume":"33","author":"McNeil","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF4","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM199305063281808","article-title":"Management of fever in patients with cancer and treatment-induced neutropenia","volume":"328","author":"Pizzo","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/jhin.2002.1278_RF5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0891-5520(20)30714-5","article-title":"Fungal infections in solid organ transplant recipients","volume":"9","author":"Hadley","year":"1995","journal-title":"Infect Dis Clin North Am"},{"key":"10.1053\/jhin.2002.1278_RF6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/bbmt.1999.v5.pm10371357","article-title":"Fungal infections after bone marrow transplant","volume":"5","author":"Wingard","year":"1999","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/jhin.2002.1278_RF7","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1046\/j.1365-2141.1999.01229.x","article-title":"Infections in adults undergoing unrelated donor bone marrow transplantation","volume":"104","author":"Williamson","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1053\/jhin.2002.1278_RF8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/321811","article-title":"National Epidemiology of Mycoses Survey (NEMIS) Study Group. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study","volume":"33","author":"Blumberg","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00006454-200004000-00011","article-title":"Risk factors for candidemia in Neonatal Intensive Care Unit patients","volume":"19","author":"Saiman","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1053\/jhin.2002.1278_RF10","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1086\/313832","article-title":"Aspergillus: an increasing problem in tertiary care hospitals?","volume":"30","author":"Chandrasekar","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/clinids\/27.5.1138","article-title":"The epidemiological features of invasive mycotic infections in the San Francisco bay area, 1992\u20131993: results of population based laboratory active surveillance","volume":"27","author":"Rees","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF12","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/clinids\/12.6.1147","article-title":"Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases","volume":"12","author":"Denning","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01709659","article-title":"Diagnosis of invasive mycoses in severely immunosuppressed patients","volume":"67","author":"Ruchel","year":"1993","journal-title":"Ann Hematol"},{"key":"10.1053\/jhin.2002.1278_RF14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/07853899908995899","article-title":"New perspectives in the diagnosis of systemic fungal infections","volume":"31","author":"Richardson","year":"1999","journal-title":"Ann Med"},{"key":"10.1053\/jhin.2002.1278_RF15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","article-title":"Amphotericin B: 30 years of clinical experience","volume":"12","author":"Gallis","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/clinids\/14.Supplement_1.S161","article-title":"Azole antifungal agents","volume":"14","author":"Bodey","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/jhin.2002.1278_RF18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-113-3-177","article-title":"Fluconazole, a new antifungal agent","volume":"113","author":"Galgiani","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1053\/jhin.2002.1278_RF19","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00003495-199039060-00006","article-title":"Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses","volume":"39","author":"Grant","year":"1990","journal-title":"Drugs"},{"key":"10.1053\/jhin.2002.1278_RF20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00003495-200161001-00004","article-title":"Clinical experience with itraconazole in systemic fungal infections","volume":"61","author":"Boogaerts","year":"2001","journal-title":"Drugs"},{"key":"10.1053\/jhin.2002.1278_RF21","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0140-6736(02)08162-X","article-title":"Antifungal drug resistance of pathogenic fungi","volume":"359","author":"Kontoyiannis","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/jhin.2002.1278_RF22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0002-9343(94)90300-X","article-title":"Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment and emergence of fluconazole resistance","volume":"97","author":"Sangeorzan","year":"1994","journal-title":"Am J Med"},{"key":"10.1053\/jhin.2002.1278_RF23","doi-asserted-by":"crossref","first-page":"175S","DOI":"10.1592\/phco.21.12.175S.34506","article-title":"A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines","volume":"21","author":"Kontoyiannis","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1053\/jhin.2002.1278_RF24","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/313498","article-title":"Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis","volume":"29","author":"Wingard","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF25","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B: recent progress and future directions","volume":"22","author":"Hiemenz","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/08982109309150729","article-title":"Development, characterization, efficacy and mode of action of AmBisome, a unilammelar liposomal formulation of amphotericin B","volume":"3","author":"Adler-Moore","year":"1993","journal-title":"J Liposome Res"},{"key":"10.1053\/jhin.2002.1278_RF27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/08982109309150730","article-title":"Amphotericin B lipid complex (ABLC\u2122): a molecular rationale for the attenuation of amphotericin B-related toxicities","volume":"4","author":"Janoff","year":"1993","journal-title":"J Liposome Res"},{"key":"10.1053\/jhin.2002.1278_RF28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0169-409X(01)00104-1","article-title":"Amphotericin B colloidal dispersion: an improved antifungal therapy","volume":"47","author":"Guo","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1053\/jhin.2002.1278_RF29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.42.4.899","article-title":"Comparison of Fungizone, Amphotec, Am-Bisome, and Abelcet for treatment of systemic murine cryptococcosis","volume":"42","author":"Clemons","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/jhin.2002.1278_RF30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-199223040-00004","article-title":"Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics","volume":"23","author":"Janknegt","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/jhin.2002.1278_RF31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/28.suppl_B.73","article-title":"Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients","volume":"28","author":"Ringden","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/jhin.2002.1278_RF32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/archinte.1995.00430100129015","article-title":"Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data","volume":"155","author":"Ng","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1053\/jhin.2002.1278_RF33","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2141.1994.tb04825.x","article-title":"Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single center experience of 133 episodes in 116 patients","volume":"86","author":"Mills","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1053\/jhin.2002.1278_RF34","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF35","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/clinids\/21.5.1145","article-title":"The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses","volume":"21","author":"Oppenheim","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1086\/516314","article-title":"Amphotericin B colloidal dispersion for the treatment of candidemia in immunocompromised patients","volume":"26","author":"Noskin","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","article-title":"Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections","volume":"103","author":"Leenders","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/jhin.2002.1278_RF38","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1053\/jhin.2002.1278_RF39","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"for the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/jhin.2002.1278_RF40","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000969","article-title":"Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia","author":"Johansen","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/jhin.2002.1278_RF41","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jac\/30.4.535","article-title":"Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients","volume":"30","author":"Moreau","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/jhin.2002.1278_RF42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/jac\/33.3.603","article-title":"A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies","volume":"33","author":"Caillot","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/jhin.2002.1278_RF43","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1177\/106002809502901201","article-title":"Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia","volume":"29","author":"Pascual","year":"1995","journal-title":"Ann Pharmacother"},{"key":"10.1053\/jhin.2002.1278_RF44","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/bmj.317.7155.379","article-title":"Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study","volume":"317","author":"Schoffski","year":"1998","journal-title":"BMJ"},{"key":"10.1053\/jhin.2002.1278_RF45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","article-title":"Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia","volume":"27","author":"White","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF46","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/10428190109097650","article-title":"Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia","volume":"40","author":"Fleming","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/jhin.2002.1278_RF48","first-page":"1","article-title":"Lipid formulations of amphotericin B","author":"Dix","year":"2000"},{"key":"10.1053\/jhin.2002.1278_RF49","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1200\/JCO.2000.18.12.2476","article-title":"Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients","volume":"18","author":"Cagnoni","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/jhin.2002.1278_RF50","article-title":"Multicenter study to evaluate the safety and efficacy of various doses of liposome-encapsulated nystatin in non-neutropenic patients with candidemia","author":"Williams","year":"1999","journal-title":"Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"10.1053\/jhin.2002.1278_RF51","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1128\/AAC.41.10.2238","article-title":"Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice","volume":"41","author":"Wallace","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/jhin.2002.1278_RF52","unstructured":"Offner, F, Herbrecht, R, Engelhard, D, et al., EORTC-IFIG phase II study on liposomal nystatin in patients with invasive aspergillosis (IA) infections, refractory or intolerant to conventional\/lipid ampho B (AB), Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"10.1053\/jhin.2002.1278_RF53","first-page":"125","article-title":"Cytochrome P450 mediated sterol synthesis and metabolism: differences in sensitivity to fluconazole and other azoles","author":"Shaw","year":"1987"},{"key":"10.1053\/jhin.2002.1278_RF54","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1093\/clinids\/12.Supplement_3.S318","article-title":"Pharmacokinetics and tissue penetration of fluconazole in humans","volume":"12","author":"Brammer","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF55","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1681\/ASN.V62242","article-title":"Pharmacokinetics of fluconazole in renal failure","volume":"6","author":"Berl","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/jhin.2002.1278_RF56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1439-0507.1998.tb00610.x","article-title":"Pharmacokinetics and dosage of fluconazole in continuous hemofiltration (CAVH, CVVH) and hemodialysis (CAVHD, CVVHD)","volume":"41","author":"Pittrow","year":"1998","journal-title":"Mycoses"},{"key":"10.1053\/jhin.2002.1278_RF57","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0959-8049(95)00619-2","article-title":"Fluconazole versus amphotericin as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial","volume":"32A","author":"Viscoli","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1053\/jhin.2002.1278_RF58","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0002-9343(98)00326-X","article-title":"A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia","volume":"105","author":"Malik","year":"1998","journal-title":"Am J Med"},{"key":"10.1053\/jhin.2002.1278_RF59","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0002-9343(99)00457-X","article-title":"A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer","volume":"108","author":"Winston","year":"2000","journal-title":"Am J Med"},{"key":"10.1053\/jhin.2002.1278_RF60","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1439-0507.2001.00649.x","article-title":"Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis","volume":"44","author":"Kontoyiannis","year":"2001","journal-title":"Mycoses"},{"key":"10.1053\/jhin.2002.1278_RF61","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/jhin.2002.1278_RF62","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/clinids\/23.5.964","article-title":"Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature","volume":"23","author":"Anaissie","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF63","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF01726360","article-title":"Multicenter randomized trial of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group","volume":"16","author":"Phillips","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF64","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1001\/archinte.1995.00430220087009","article-title":"Therapeutic approaches in patients with candidemia","volume":"155","author":"Nguyen","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1053\/jhin.2002.1278_RF65","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0002-9343(96)80072-6","article-title":"Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study","volume":"101","author":"Anaissie","year":"1996","journal-title":"Am J Med"},{"key":"10.1053\/jhin.2002.1278_RF66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s001340050286","article-title":"Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy","volume":"23","author":"Nolla-Salas","year":"1997","journal-title":"Intensive Care Med"},{"key":"10.1053\/jhin.2002.1278_RF67","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200161001-00003","article-title":"Pharmacology of itraconazole","volume":"61","author":"De Beule","year":"2001","journal-title":"Drugs"},{"key":"10.1053\/jhin.2002.1278_RF68","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","article-title":"Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics","volume":"26","author":"Willems","year":"2001","journal-title":"J Clin Pharm Ther"},{"key":"10.1053\/jhin.2002.1278_RF69","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1592\/phco.19.8.603.31529","article-title":"Itraconazole in cyclodextrin solution","volume":"19","author":"Stevens","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1053\/jhin.2002.1278_RF70","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1345\/aph.10262","article-title":"Intravenous itraconazole","volume":"35","author":"Slain","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1053\/jhin.2002.1278_RF71","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003088-199835060-00004","article-title":"Optimisation of itraconazole therapy using target drug concentrations","volume":"35","author":"Poirier","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/jhin.2002.1278_RF72","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1034\/j.1399-3062.2000.020205.x","article-title":"The use of itraconazole as prophylaxis against invasive fungal infection in blood and marrow transplant recipients","volume":"2","author":"Boyle","year":"2000","journal-title":"Transpl Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF73","first-page":"535","article-title":"An important drug interaction","volume":"12","author":"Williams","year":"1998","journal-title":"Can J Gastroenterol"},{"key":"10.1053\/jhin.2002.1278_RF74","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2125.2001.01372.x","article-title":"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects","volume":"51","author":"Lebrun-Vignes","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/jhin.2002.1278_RF75","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0009-9236(98)90066-2","article-title":"Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole","volume":"64","author":"Varis","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/jhin.2002.1278_RF76","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2125.1991.tb03963.x","article-title":"Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes","volume":"32","author":"Back","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/jhin.2002.1278_RF77","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/S0140-6736(00)04891-1","article-title":"Congestive heart failure associated with itraconazole","volume":"357","author":"Ahmad","year":"2001","journal-title":"Lancet"},{"key":"10.1053\/jhin.2002.1278_RF78","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0163-4453(94)95941-2","article-title":"Treatment of invasive aspergillosis","volume":"28","author":"Denning","year":"1994","journal-title":"J Infect"},{"key":"10.1053\/jhin.2002.1278_RF79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1086\/323020","article-title":"Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS","volume":"33","author":"Caillot","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF80","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000059317","article-title":"Antifungal prophylaxis in neutropenic patients with hematologic malignancies","volume":"50","author":"Bohme","year":"2000","journal-title":"Antibiot Chemother"},{"key":"10.1053\/jhin.2002.1278_RF81","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1439-0507.1996.tb00134.x","article-title":"Antifungal prophylaxis with itraconazole in neutropenic patients: pharmacological, microbiological and clinical aspects","volume":"39","author":"Glasmacher","year":"1996","journal-title":"Mycoses"},{"key":"10.1053\/jhin.2002.1278_RF82","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7326\/0003-4819-135-6-200109180-00010","volume":"135","author":"Boogaerts","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1053\/jhin.2002.1278_RF83","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF84","article-title":"Voriconazole (VORI) for the treatment of resistant and rare fungal pathogens","author":"Perfect","year":"2000","journal-title":"Proceedings of the 38th Annual Meeting of the Infectious Diseases Society of America"},{"key":"10.1053\/jhin.2002.1278_RF85","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00006454-200203000-00015","article-title":"Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children","volume":"21","author":"Walsh","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1053\/jhin.2002.1278_RF86","article-title":"Open, randomized comparison of voriconazole (VRC) and amphotericin B (AmB) followed by other licensed antifungal therapy of invasive aspergillosis (IA)","author":"Herbrecht","year":"2001","journal-title":"Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"10.1053\/jhin.2002.1278_RF87","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/02681219880000361","article-title":"In vitro activity of voriconazole against selected fungi","volume":"36","author":"McGinnis","year":"1998","journal-title":"Med Mycol"},{"key":"10.1053\/jhin.2002.1278_RF88","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1128\/JCM.36.1.198-202.1998","article-title":"In vitro activity of the new triazole voriconazole (UK-109-496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens","volume":"36","author":"Espinel-Ingroff","year":"1998","journal-title":"J Clin Microbiol"},{"key":"10.1053\/jhin.2002.1278_RF89","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/42.6.741","article-title":"In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fuigi","volume":"42","author":"Johnson","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/jhin.2002.1278_RF90","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1054-3589(08)60129-5","article-title":"Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development","volume":"44","author":"Groll","year":"1998","journal-title":"Adv Pharmacol"},{"key":"10.1053\/jhin.2002.1278_RF91","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"for The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/jhin.2002.1278_RF92","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1128\/AAC.42.4.993","article-title":"in vitro activity of a new oral triazole, BMS-207147 (ER-30346)","volume":"42","author":"Fung-Tomc","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/jhin.2002.1278_RF93","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1128\/AAC.45.7.2151-2153.2001","article-title":"In vitro activities of four novel triazoles against Scedosporium spp","volume":"45","author":"Carrillo","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/jhin.2002.1278_RF94","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1128\/AAC.44.12.3381-3388.2000","article-title":"Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis","volume":"44","author":"Roberts","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/jhin.2002.1278_RF95","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1128\/AAC.44.10.2883-2886.2000","article-title":"In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans","volume":"44","author":"Yamazumi","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/jhin.2002.1278_RF96","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1128\/AAC.45.3.857-869.2001","article-title":"Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia","volume":"45","author":"Petraitiene","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/jhin.2002.1278_RF97","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/46.2.229","article-title":"A comparative study of the in vitro susceptibilities of clinical and laboratory- selected resistant isolates ofAspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592)","volume":"46","author":"Manavathu","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/jhin.2002.1278_RF98","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1128\/AAC.44.8.2017-2022.2000","article-title":"In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, againstAspergillus and Candida","volume":"44","author":"Cacciapuoti","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/jhin.2002.1278_RF99","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1006970503053","article-title":"In vitro activity of a new triazole antifungal agent SCH56592, against clinical isolates of filamentous fungi","volume":"141","author":"Marco","year":"1998","journal-title":"Mycopathologia"},{"key":"10.1053\/jhin.2002.1278_RF100","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1128\/AAC.44.10.2604-2608.2000","article-title":"Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice","volume":"44","author":"Connolly","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/jhin.2002.1278_RF101","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1128\/AAC.45.5.1355-1359.2001","article-title":"Interactions of posaconazole and flucytosine against Cryptococcus neoformans","volume":"45","author":"Barchiesi","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/jhin.2002.1278_RF102","article-title":"An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections (IFI) refractory\u00ae to or intolerant (I) to standard therapy (ST)","author":"Hachem","year":"2000","journal-title":"Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"10.1053\/jhin.2002.1278_RF103","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/13543784.10.2.269","article-title":"Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors","volume":"10","author":"Georgopapadakou","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1053\/jhin.2002.1278_RF104","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev.mi.48.100194.002351","article-title":"Antibiotics that inhibit fungal cell wall development","volume":"48","author":"Debono","year":"1994","journal-title":"Annu Rev Microbiol"},{"key":"10.1053\/jhin.2002.1278_RF105","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/AAC.44.2.368-377.2000","article-title":"Discovery of novel antifungal (1,3) \u03b2-D-glucan synthase inhibitors","volume":"44","author":"Onishi","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/jhin.2002.1278_RF106","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/BF01975172","article-title":"Effects of cilofungin (LY121019) on carbohydrate and sterol composition of Candida albicans","volume":"8","author":"Pfaller","year":"1989","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF107","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/173.3.684","article-title":"Identification of a glucan-associated enolase as a main cell wall protein of Candida albicans and an indirect target of lipopeptide antimycotics","volume":"173","author":"Angiolella","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF108","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00001432-200112000-00004","article-title":"Clinical efficacy of echinocandins antifungals","volume":"14","author":"Arathon","year":"2001","journal-title":"Curr Opin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF109","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jac\/40.5.611","article-title":"Echinocandins and pneumocandins: a new antifungal class with a novel mode of action","volume":"40","author":"Denning","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/jhin.2002.1278_RF110","article-title":"Synergistic effects of combination of FK463 with amphotericin B: enhanced efficacy in murine model of invasive pulmonary aspergillosis","author":"Kohno","year":"2000","journal-title":"Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"10.1053\/jhin.2002.1278_RF111","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/AAC.46.1.245-247.2002","article-title":"in vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp","volume":"46","author":"Arikan","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/jhin.2002.1278_RF112","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.44.9.2310-2318.2000","article-title":"Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice","volume":"44","author":"Abruzzo","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1053\/jhin.2002.1278_RF113","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1086\/323401","article-title":"A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis","volume":"33","author":"Villanueva","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF114","article-title":"Efficacy of caspofungin as a salvage therapy in invasive aspergillosis as compared to standard therapy in a historical cohort","author":"Maertens","year":"2001","journal-title":"Proceedings of the 11th European Congress of Clinical Microbiology and Infectious Diseases"},{"key":"10.1053\/jhin.2002.1278_RF115","article-title":"Caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients: a multicentre, randomized, double blind study","author":"Mora-Duarte","year":"2002","journal-title":"Proceedings of the 12th European Congress of Clinical Microbiology and Infectious Diseases"},{"key":"10.1053\/jhin.2002.1278_RF116","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.7164\/antibiotics.53.1175","article-title":"In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens","volume":"53","author":"Uchida","year":"2000","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1053\/jhin.2002.1278_RF117","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jac\/46.3.485","article-title":"In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide","volume":"46","author":"Mikamo","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/jhin.2002.1278_RF118","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1469-0691.2001.00158.x","article-title":"In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species","volume":"7","author":"Moore","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1053\/jhin.2002.1278_RF119","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jac\/46.3.475","article-title":"Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B","volume":"46","author":"Cuenca-Estrella","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/jhin.2002.1278_RF120","series-title":"Candidiasis: Pathogenesis, Diagnosis, and Treatment","author":"Bodey","year":"1993"},{"key":"10.1053\/jhin.2002.1278_RF121","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/520192","article-title":"Nosocomial bloodstream infections in United States hospitals: a three-year analysis","volume":"29","author":"Edmond","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF122","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jac\/29.suppl_A.19","article-title":"Predominant pathogens in hospital infections","volume":"29","author":"Jarvis","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"10.1053\/jhin.2002.1278_RF123","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1086\/313450","article-title":"The epidemiology of candidemia in two United States cities: results of a population-based active surveillance","volume":"29","author":"Kao","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF124","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1086\/318473","article-title":"Candida lusitaniae: a cause of breakthrough fungemia in cancer patients","volume":"32","author":"Minari","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF125","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/003655401750065544","article-title":"Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital","volume":"33","author":"Baran","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF126","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1086\/320757","article-title":"Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia","volume":"32","author":"Uzun","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF127","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/clind\/15.3.414","article-title":"Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality","volume":"15","author":"Fraser","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0002-9343(79)90073-1","article-title":"Hospital-acquired fungemia: its natural course and clinical significance","volume":"67","author":"Klein","year":"1979","journal-title":"Am J Med"},{"key":"10.1053\/jhin.2002.1278_RF129","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1001\/archinte.1987.00370120053011","article-title":"Nosocomial fungemia in a large community teaching hospital","volume":"147","author":"Harvey","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1053\/jhin.2002.1278_RF130","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/clinids\/11.3.379","article-title":"Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome","volume":"11","author":"Komshian","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF131","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/clinids\/7.5.646","article-title":"Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy","volume":"7","author":"Horn","year":"1985","journal-title":"Rev Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF132","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1001\/archinte.1988.00380120094019","article-title":"Hospital-acquired candidemia: the attributable mortality and excess length of stay","volume":"148","author":"Wey","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1053\/jhin.2002.1278_RF133","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/514955","article-title":"The impact of candidemia on length of hospital stay, outcome, and overall cost of illness","volume":"27","author":"Rentz","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF134","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00002030-200102002-00003","article-title":"Immune restoration and CD4+ T-cell function with antiretroviral therapies","volume":"15","author":"Lederman","year":"2001","journal-title":"AIDS"},{"key":"10.1053\/jhin.2002.1278_RF135","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/313843","article-title":"Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy","volume":"30","author":"Kaplan","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF136","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1086\/313749","article-title":"Practice guidelines for the treatment of candidiasis","volume":"30","author":"Rex","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF137","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/clinids\/24.2.235","volume":"24","author":"Rex","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF138","first-page":"99","article-title":"Outcome of treatment of candidemia in children whose central catheters were removed or retained","volume":"8","author":"Eppes","year":"1989","journal-title":"Pediatr Infect Dis J"},{"key":"10.1053\/jhin.2002.1278_RF139","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00006454-199005000-00002","article-title":"Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy","volume":"9","author":"Dato","year":"1990","journal-title":"Pediatr Infect Dis J"},{"key":"10.1053\/jhin.2002.1278_RF140","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/clinids\/14.4.875","article-title":"Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes","volume":"14","author":"Lecciones","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF141","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/clinids\/21.4.994","article-title":"Intravascular catheter exchange in duration of candidemia","volume":"21","author":"Rex","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF142","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10096-002-0699-z","article-title":"Invasive aspergillosis in 2002: an update","volume":"21","author":"Kontoyiannis","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF143","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-4453(96)92700-0","article-title":"Trends in the postmortem epidemiology of invasive fungal infections at a university hospital","volume":"33","author":"Groll","year":"1996","journal-title":"J Infect"},{"key":"10.1053\/jhin.2002.1278_RF144","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1093\/clinids\/19.Supplement_1.S41","article-title":"Invasive aspergillosis in patients with AIDS","volume":"19","author":"Khoo","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF145","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1128\/CMR.12.2.310","article-title":"Aspergillus fumigatus and aspergillosis","volume":"12","author":"Latge","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"10.1053\/jhin.2002.1278_RF146","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1086\/520297","article-title":"Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature","volume":"26","author":"Iwen","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF147","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/clinids\/23.3.608","article-title":"Therapeutic outcome in invasive aspergillosis","volume":"23","author":"Denning","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF148","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1086\/313756","article-title":"Practice guidelines for diseases caused by Aspergillus","volume":"30","author":"Stevens","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF149","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1086\/313750","article-title":"Practice guidelines for the management of patients with blastomycosis","volume":"30","author":"Chapman","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF150","first-page":"243","article-title":"Blastomycosis in the immunocompromised patient","volume":"12","author":"Pappas","year":"1997","journal-title":"Semin Respir Infect"},{"key":"10.1053\/jhin.2002.1278_RF151","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/clinids\/16.1.54","article-title":"Blastomycosis in transplant recipients: report of a case and review","volume":"16","author":"Serody","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF152","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1086\/313752","article-title":"Practice guidelines for the management of patients with histoplasmosis","volume":"30","author":"Wheat","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF153","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/313757","article-title":"Practice guidelines for the management of cryptococcal disease","volume":"30","author":"Saag","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF154","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1086\/516372","article-title":"Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS","volume":"26","author":"Mayanja-Kizza","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","article-title":"Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group","volume":"337","author":"van der Horst","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/jhin.2002.1278_RF156","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/clinids\/19.4.741","article-title":"Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS","volume":"19","author":"Larsen","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF157","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1093\/clinids\/14.Supplement_1.S54","article-title":"Therapy for cryptococcal meningitis in patients with AIDS","volume":"14","author":"Powderly","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF158","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1086\/313747","article-title":"Practice guidelines for the treatment of coccidioidomycosis","volume":"30","author":"Galgiani","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF159","first-page":"163","article-title":"Coccidioidal meningitis","author":"Kelly","year":"1980"},{"key":"10.1053\/jhin.2002.1278_RF160","first-page":"207","article-title":"Coccidioidomycosis","author":"Stevens","year":"1991"},{"key":"10.1053\/jhin.2002.1278_RF161","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1086\/313751","article-title":"Practice guidelines for the management of patients with sporotrichosis","volume":"30","author":"Kauffman","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF162","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/CMR.7.4.479","article-title":"Taxonomy, biology, and clinical aspects of Fusarium species","volume":"7","author":"Nelson","year":"1994","journal-title":"Clin Microbiol Rev"},{"key":"10.1053\/jhin.2002.1278_RF163","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1086\/319753","article-title":"Fusarium infection after solid-organ transplantation","volume":"32","author":"Sampathkumar","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF164","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1365-2141.2000.02312.x","article-title":"The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme","volume":"111","author":"Girmenia","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1053\/jhin.2002.1278_RF165","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V90.3.999","article-title":"Fusarium, a significant emerging pathogen in patients with hematologic malignancy: 10 years' experience at a cancer center and implications for management","volume":"90","author":"Boutati","year":"1997","journal-title":"Blood"},{"key":"10.1053\/jhin.2002.1278_RF166","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1093\/clinids\/22.Supplement_2.S112","article-title":"The new fungal opportunists are coming","volume":"22","author":"Perfect","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1053\/jhin.2002.1278_RF167","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0195-6701(99)90015-4","article-title":"Invasive yeast infections other than Candida spp. in acute leuk aemia","volume":"41","author":"Krcmery","year":"1999","journal-title":"J Hosp Infect"}],"container-title":["Journal of Hospital Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195670102912788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195670102912788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T19:29:52Z","timestamp":1622834992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0195670102912788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":167,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["S0195670102912788"],"URL":"https:\/\/doi.org\/10.1053\/jhin.2002.1278","relation":{},"ISSN":["0195-6701"],"issn-type":[{"value":"0195-6701","type":"print"}],"subject":[],"published":{"date-parts":[[2003,4]]}}}